key: cord-1043981-yy0n60xt authors: Mahboubi Mehrabani, Mohammad; Karvandi, Mohammad Sobhan; Maafi, Pedram; Doroudian, Mohammad title: Neurological complications associated with Covid‐19; molecular mechanisms and therapeutic approaches date: 2022-02-09 journal: Rev Med Virol DOI: 10.1002/rmv.2334 sha: eacfbf4d0b6dbaebcefa25776aa0be169d335fd8 doc_id: 1043981 cord_uid: yy0n60xt With the progression of investigations on the pathogenesis of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), neurological complications have emerged as a critical aspect of the ongoing coronavirus disease 2019 (Covid‐19) pandemic. Besides the well‐known respiratory symptoms, many neurological manifestations such as anosmia/ageusia, headaches, dizziness, seizures, and strokes have been documented in hospitalised patients. The neurotropism background of coronaviruses has led to speculation that the neurological complications are caused by the direct invasion of SARS‐CoV‐2 into the nervous system. This invasion is proposed to occur through the infection of peripheral nerves or via systemic blood circulation, termed neuronal and haematogenous routes of invasion, respectively. On the other hand, aberrant immune responses and respiratory insufficiency associated with Covid‐19 are suggested to affect the nervous system indirectly. Deleterious roles of cytokine storm and hypoxic conditions in blood‐brain barrier disruption, coagulation abnormalities, and autoimmune neuropathies are well investigated in coronavirus infections, as well as Covid‐19. Here, we review the latest discoveries focussing on possible molecular mechanisms of direct and indirect impacts of SARS‐CoV‐2 on the nervous system and try to elucidate the link between some potential therapeutic strategies and the molecular pathways. sequence identity in the Spike protein, and both utilise the human angiotensin converting enzyme 2 (hACE2) receptor of the host cell for cell entry. [25] [26] [27] Noteworthy, the binding affinity of SARS-CoV-2 S protein to ACE2 receptor is 10-20 times higher than that of SARS-CoV due to some structural differences in the receptor binding domain of S protein. 28, 29 In addition, the production of angiotensin II (Ang II) is counterbalanced by ACE2. The primary function of ACE2 is the degradation of Ang II and formation of Ang 1-7 to neutralise the vasoconstrictor effect of Ang II and maintain blood pressure. 26, 27, [29] [30] [31] ACE2 is highly expressed in the small intestine, kidney, heart, adipose tissue, thyroid, testis, and pancreas, whereas the muscles, brain, spleen, and blood vessels have the lowest ACE2 expression. 32, 33 Besides, lungs, liver, bladder, and colon have shown a medium ACE2 expression. [33] [34] [35] Moreover, ACE2 receptor is expressed in higher levels in the lungs of smokers and type 2 diabetes (T2D) patients and in the heart of patients with cardiovascular disease (CVD), which makes them more susceptible to be infected by SARS-CoV-2. 33 In addition, an increase in mRNA levels of ACE2 in Covid-19 patients has been reported. 33 Low expression of ACE2 in respiratory tissues and high rates of infection in these tissues, lead to the speculation of plausible alternative receptors. Several experiments support the role of co-receptors and attachment factors such as transmembrane serine protease 2 (TMPRSS2), basigin (BSG) (also known as CD147), GRP78, some toll-like receptors (TLRs) and c-type lectin receptors (CLRs), heparan sulfate, and sialic acids, which facilitate and enhance the entry of the virus in the presence of ACE2. 26, 33, 36 Nevertheless, these co-receptors may not be sufficient for virus entry into some specific cells not expressing ACE2 although deletion of co-receptors may reduce infection. 26, 33, [37] [38] [39] Furthermore, Neuropilin 1 (NRP1) mainly facilitates the regulation of angiogenesis, gangliogenesis, and vascular permeability, and similarly, enhances viral infectivity and acts as a co-receptor for cell entry. 26, 40 Noteworthy, NRP1 and BSG are found more than ACE2 and TMPRSS2 in the brain, including the olfactory bulb (OB). 39 The pathogenesis of SARS-CoV-2 is mediated via the interaction between receptors and the spike protein of the virus for viral attachment, then utilising diverse endocytic pathways for entry. 41, 42 To elaborate, after binding the receptor binding domain of S protein to the peptidase domain of ACE2, the SARS-CoV-2/ACE2 complex is formed. Subsequently, TMPRSS2, which activates and cleaves S protein, 25, 28, 29 is activated for S priming, and then the SARS-CoV-2/ ACE2 complex undergoes endocytosis and forms an endosome. After acidification of the endosome and fusion of viral and lysosomal membranes, 41 encapsidated viral RNA is released to the cytoplasm for replication and transcription. 26, 42, 43 Complementary to this, SARS-CoV-2 may utilise CD147-mediated endocytosis for cell entry, 44 and pro-protein convertase furin (PCF) might also play a role in endocytic pathways.PCF is essential for the propagation of numerous viruses by cleavage of viral envelope glycoproteins, which may also involve the endocytosis of SARS-CoV-2. 45 Due to the expression of ACE2 and CD147 and other plausible receptors in the circumventricular organs of CNS, glial cells, and neurons, 30, 31, 46, 47 SARS-CoV-2 can potentially invade the nervous system, which leads to neurological manifestations. Neurological impairments are not limited to direct infection by the virus. Other indirect effects of infection, including the immune response and cytokine storm, can also damage the nervous system, as explained in subsequent sections of this review. 48 Considering the high pathophysiological pathway similarity between SARS-CoV and SARS-CoV-2, they might share putative routes for CNS invasion, which are elaborated below. The main transmission factor of SARS-CoV-2 is the droplets of Covid-19 patients who cough and sneeze and release the droplets into the air. 49 Thus, clarifying the potential intranasal and oral routes of SARS-CoV-2 CNS invasion is required to understand the 2 of 21development of anosmia, ageusia, and other nervous system dysfunctions. After entering via droplets containing SARS-CoV-2 in the nasal cavity, viruses can either reach the lung through the airway or land on the nasal mucosa and infect susceptible cells. 50 The olfactory epithelium (OE) of the nasal cavity contains olfactory sensory neurons (OSNs), basal cells, epithelial cilia, and Bowman's gland for mucus secretion and homoeostatic electrolyte balance 51 (Figure 1a ). Horizontal basal cells (HBCs) of the OE are directly attached to the basal lamina and are progenitors of OSNs. It is believed that OSNs do not express ACE2; it is expressed in HBCs, which then mature into OSNs. Infected HBCs mature into bipolar unmyelinated OSNs and then penetrate the cribriform plate and access the OB by a synaptic path 39, [52] [53] [54] (Figure 1b) . Subsequently, the virus could infect mitral cells of the OB, which are connected to several parts of the brain, and facilitate infection of other susceptible regions of the nervous system, including the cortex, the mesolimbic cortex, hippocampus, amygdala, and eventually brainstem and spinal cord via a transsynaptic pathway, using endocytosis and exocytosis 39, 48 (Figure 1d ). Similar animal experiments using MERS-CoV, SARS-CoV, and SARS-CoV-2 support HBC and OSN infection as a precurser to reaching the CNS via olfactory nerves. [55] [56] [57] The majority of Covid-19 patients experience smell or taste disorders [58] [59] [60] [61] ; this neurotoxic effect of SARS-CoV-2 might be due to changes in phosphorylation pattern of proteins associated with axons and synapses in olfactory/gustatory neurons or injuries to any of VII, IX, X cranial nerves and the nucleus of solitary tract. 50, 62 Moreover, the molecular mechanism of virus transportation inside PNS and brain parenchyma neurons is almost identified in the neuronal route. Due to the high length of peripheral nerve axons, the migration of the virus via diffusion could not be possible. 62 Thus, experimental results suggest another propagation mechanism named fast axonal transport (FAT), which is mainly used by hCoVs to spread along neuronal cells. 63 After the endocytosis of the virus to peripheral neurons and formation of the endosomes, the endosome lysis occurs, and the virus undergoes retrograde trafficking to the cell body and nucleus via axonal microtubules, utilising the microtubule-dependent motor proteins kinesin for anterograde and dynein for retrograde axonal transport. 48, 62, 64, 65 Therefore, the envelope of SARS-CoV-2 should be stable during neuronal transport 66 (Figure 1c ). In addition to the olfactory nerve, the virus could utilise other peripheral nerves to reach the CNS and brainstem, including the pulmonary network and enteric nervous system (ENS) via the vagus nerve. 50, 53, 66, 67 NRP1 and ACE2 are highly expressed in the gastrointestinal tract; meanwhile, intestinal neurons and glia highly express ACE2 and TMPRSS2 and are susceptible to being infected by SARS-CoV-2. 39, 49, 64 In addition, viral nucleic acid has been detected in the stool of Covid-19 patients, [68] [69] [70] [71] which may be due to the infection of intestinal cells or self-ingestion of mucus from the airways. 72 The enteric neuronal network is directly connected to the CNS through the parasympathetic vagus nerve arising from the hindbrain, and the sympathetic nerve fibres arising from the spine. 66 Hence, transferring the infection from the intestine to the CNS is possible in animal models. At the same time, there is not sufficient evidence in humans and requires attaining more data of vagal complex ACE2 expression and the ability of trans-neuronal spread of SARS-CoV-2 in the gutbrain axis. 39 In brief, considering the anatomically close distance of the olfactory nerves to the CNS, it can be suggested as the main pathway of neuronal dissemination of SARS-CoV-2 to reach the CNS in the early stages of the infection rather than the gut-brain axis or other plausible neuronal routes. As the second possible infectivity route, haematogenous dissemination of viral particles could provide entry into the CNS for SARS-CoV-2 via overcoming the barriers of CNS or through circumventricular organs. [73] [74] [75] Despite the wide range of frequency in results of different studies, dissemination of SARS-CoV-2 into the blood has been reported in up to 40% of patients with Circulating viral particles could cross the blood-brain barrier (BBB) and invade the brain parenchyma, facilitating ACE2 receptors that are expressed by brain endothelial cells (ECs) and pericytes 74, 77, 78 ( Figure 2a ). In vitro, human vessel organoids are susceptible to SARS-CoV-2 infection in an ACE2-dependent manner. 79 In line with this, clinical studies have observed the presence of viral elements in ECs of multiple organs in Covid-19 patients; more specifically, an autopsy study in which electron micrographs indicated the presence of SARS-CoV-2 viral-like proteins inside ECs of frontal lobe tissue of the brain. 80, 81 Of note, there is evidence of cerebral vasculature wide expression of some SARS-CoV-2 alternative receptors such as NRP1 and BSG, which could be considered a synergistic factor for this entry route. 39, 76, 82 Moreover, increased secretion of pro-inflammatory cytokines and chemokines and pneumonia-induced hypoxia associated with Covid-19 compromise the BBB integrity, expedite virus entry and contribute to CNS invasion by SARS-CoV-2. 74, 83, 84 The choroid plexus and circumventricular organs are other regions that could possibly act as entry gates to the brain for circulating SARS-CoV-2 particles. Termed as the blood-CSF barrier, the choroid plexus is the selectively permeable structure that restricts the free diffusion of molecules at the blood-CSF interface and contributes to CSF production. 64, 78 ACE2 and TMPRSS2 are expressed by human choroid plexus cells, 85 Dissemination of virus-infected leucocytes into the' blood circulation and subsequent extravasation of the immune cells into the brain parenchyma could serve as another gateway for the virus to the CNS. The so-called 'Trojan horse' mechanism has been well investigated previously in some of the neurotropic viruses such as F I G U R E 1 Potential route of central nervous system invasion of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) via nasal cavity and axonal transport propagation. (a) Olfactory epithelium is located in the roof of the nasal cavity and its distinct cell types; (b) Proposed mechanism of olfactory sensory neuron (OSN) infection process by infection and differentiation of horizontal basal cells (HBCs) to OSNs and propagation of viruses to the olfactory bulb (OB) through the cribriform plate; (c) Axonal transport of viruses via retrograde and anterograde dissemination utilising Dynein for retrograde and Kinesin for anterograde transport to facilitate the infection of neuronal cells; (d) Trans-synaptic pathway of virus propagation in the OB to infiltrate in the brain and infect more cells by exocytosis and endocytosis HIV and West Nile Virus (WNV). 91, 92 Infected leucocytes could infiltrate into the brain through the vasculature, the meninges, and the choroid plexus. These sites have been observed as entry points for monocytes, neutrophils, and T cells. 77 There are indications that SARS-CoV could infect lymphocytes, granulocytes, monocytes, and monocyte derivatives 93 ; thus, it is likely that SARS-CoV-2 also utilises this mechanism in order to invade the CNS by infecting ACE2expressing leucocytes. 45,94 SARS-CoV-2 is shown to abortively infect dendritic cells and macrophages. 95 This evidence, in conjunction with systemic inflammation and hypoxic condition that increase the infiltration of leucocytes through the BBB during the infection, 45, 96 strengthens the feasibility of SARS-CoV-2 neuroinvasion by this route (Figure 2d ). 100 In contrast, no decrease of B-cells has been seen in Covid-19 patients. 99 Cytokines, the main indication of hyper-inflammation in Covid-19 patients, are a group of immunoregulatory cell-cell communication molecules, including chemokines, interleukins, lymphokines, monokines, and interferons. 101 Chemokines such as CXCL8 and CXCL10 act as chemotaxis cytokines F I G U R E 2 Possible mechanisms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) haematogenous route of neuroinvasion. (a) Blood-brain barrier (BBB). Brain endothelial cells (ECs) and pericytes are observed to express angiotensin converting enzyme 2 (ACE2) and other SARS-CoV-2 alternative receptors. This could facilitate the SARS-CoV-2 invasion to the brain tissue through the paracellular passage of the viral particles across the BBB; (b) choroid plexus. The barrier at the interface between the blood and the cerebrospinal fluid (CSF) consists of a more permeable endothelium due to the fenestrated structure of the ECs. Moreover, the choroid plexus epithelium cells at the apical side of the blood-CSF barrier express ACE2. With these properties, the blood-CSF barrier could serve as a SARS-CoV-2 entry gate to the CSF and then brain parenchyma; (c) circumventricular organs. Capillaries of the median eminence and other circumventricular organs lack the tightly coordinated BBB structure and consist of a continuous, fenestrated endothelium permeable to polypeptides and hormone molecules. Due to this extensive permeability, circumventricular organs could act as possible gateways to the brain tissue for SARS-CoV-2; (d) Trojan horse mechanism. SARS-CoV-2 could infect the leucocytes. Dissemination of infected leucocytes into the cerebral blood circulation and later extravasation of infected cells could facilitate SARS-CoV-2 entry to the brain parenchyma by the so-called Trojan horse mechanism MAHBOUBI MEHRABANI ET AL. and bring leucocytes to the site of concern. 102,103 Additionally, the production of type I interferons is the fastest and first response of infected cells to slow down or stop viral replication and alert the presence of the pathogen to immune cells. 74, 102 Although cytokines are essential for combating viral infections, overexpression and elevated levels of inflammatory cytokines, known as cytokine storm, could lead to immune cell infiltration to different organs, which subsequently causes multiple organ damage such as acute respiratory distress syndrome (ARDS) and CNS dysfunction or even death. 100, 101, [104] [105] [106] [107] According to obtained data, the majority of se- patients, making them susceptible to complement-mediated injuries. 114, 115 The generation of IFNs and other cytokines is mediated through several pattern-recognition receptors (PRRs), including TLRs and NOD-like receptors (NLRs), which are expressed in monocytes, neutrophils, macrophages, and dendritic cells. 116 PRRs detect pathogen-associated molecular patterns (PAMPs) and damageassociated molecular patterns (DAMPs), including viral components such as RNA and molecular complexes from damaged cells. 76 As an example, TLR3 expressed on ECs recognises viral RNA and consequently increases the release of IFNs. 74 Besides, by activating the PRRs, formation of inflammasomes is promoted, and procaspase-1 converts to caspase-1, leading to converting pro-IL-1β to the active IL-1β. 106 The triggered signalling process leads to the expression or activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) as well as activation of interferon regulatory factors that mediate the type I interferon-dependent anti-viral response, which involves in the activation of innate immunity. 106, 113, 117 SARS-CoV-2 infection may also induce a massive release of ATP in the alveolar microenvironment that ATPs can act as DAMP and can activate P2X7R and NLRP3, which eventually results in the progression of inflammatory response and IL-1β and IL-18 release. 97, 118 P2X7 receptors are widely expressed in immune, lung, and CNS cells, mainly in microglia and oligodendrocytes, and play a key role in inflammation. 119 NLRP3 inflammasome is an essential cause of activation of the innate immune response, 113 and unlike other PRRs, NLRP3 can react to other signals such as K+ efflux, production of reactive oxygen species (ROS), and Ca2+ mobilisation. 120 For instance, P2X7R activation triggers K+ efflux, which then stimulates the NLRP3 inflammasome and cytokine release. 120 Hence, upregulation of transcription of NLRP3 genes may help the recognition of PAMPs and DAMPs that may be induced by activation of purine sensing receptors such as P2X7R and results in cytokine release. 113, 119 Another involved pathway in the activation of cytokines such as type I IFNs after viral infection is the Janus kinase-signal transducer and activator of transcription (JAK-STAT) signalling pathway. 121 This pathway mediates biologic activity for a large number of inflammatory cytokines, which demonstrates JAK-STAT activation contribution to critical events such as inflammation and the development of the immune system, which may lead to facilitating the invasion of SARS-CoV-2 into the CNS. 104, 122 Since multiple pathways control cytokine activation, 101 the inhibition of involved pathways looks to be a promising strategy to balance the immune response. 123 However, prolonged inhibition of plausible pathways associated with cytokine release or activation may lead to a compromised anti-viral immune response, which could subsequently promote the proliferation of the SARS-CoV-2. 104,106 Therefore, clinical trials are in progress focussing on inhibiting associated inflammatory molecules or receptors and pathways to overcome the hyper-inflammation and prevent harmful effects arising from the hyper-inflammatory response of SARS-CoV-2 infection (Table 1) . Segregating the CNS from peripheral blood circulation, the BBB is a highly selective barrier formed by unique ECs and supporting cellular and non-cellular elements, including astrocytes, pericytes, and extracellular matrix (ECM). As a part of the 'neurovascular unit' (NVU), the highly coordinated activity of BBB components results in tight control of molecules and ions passage, precise delivery of oxygen and nutrients according to tissue needs, and protection of the CNS from toxins and pathogens. 124, 125 The balanced permeability of BBB is crucial for the maintenance of an environment that neurons could properly function in 126 ; however, emerging evidence suggests that SARS-CoV-2 infection has the potency to disturb the integrity of BBB and induce hyperpermeability in the barrier. A recent study in a BBB-on-a-chip in vitro system demonstrated that the SARS-CoV-2 spike protein could cause dysfunction and loss of integrity of the BBB. 127 In line with this, a case study of 31 Covid-19 patients with neurological manifestations reported that 58% of patients exhibited signs of BBB disruption and leakage. 128 As the core anatomical elements of the BBB, ECs in the brain are uniquely specialised in structure and function. Continuous intercellular tight junctions (TJs), lack of common fenestrations, and suppressed transcytosis are distinguishing characteristics of these cells, compared to ECs in other tissues, making them capable of limiting both the paracellular and transcellular passage of molecules through the neurovascular endothelium. 89, 124 However, barrier properties of brain ECs could be altered directly or/and indirectly by the virus infection. Because of the fact that expression of ACE2 receptor and NRP1 has been observed in human brain microvascular ECs, 77, 133 and the presence of SARS-CoV-2 particles in capillary ECs of the brain is reported in an autopsy study, 80 ECs could be proposed as a possible route of damage to the BBB ( Figure 3a) ; however, the indirect effect of the hyperinflammatory state is the most likely culprit of disruption of the BBB associated with Covid-19. 45 Elevation in levels of pro-inflammatory factors is strongly related to alteration in TJ function and BBB disruption. For instance, . SARS-CoV-2 could also infect leucocytes; (b) by facilitating entry receptors, SARS-CoV-2 infects the brain ECs and promotes activation of these cells. Moreover, due to systemic inflammation associated with the infection, ECs exposure to circulating cytokines also activates these cells. ECs activation induces upregulated expression of vascular and intercellular adhesion molecules (VCAM and ICAM) and matrix metalloproteinases (MMPs). Interaction of leucocyte surface β1 and β2 integrins with adhesion molecules results in the binding of circulating leucocytes to the ECs and facilitates extravasation of leucocytes through the tight junctions and basement membrane that are already degraded by the action of MMPs. In this manner, infiltration of infected leucocytes by the 'Trojan horse' mechanism facilitates viral entry to the brain parenchyma; (c) infection of the brain ECs and hyperinflammatory state associated with Covid-19 induce apoptosis of ECs, leading to the disruption of the BBB. The compromised barrier allows extravasation of erythrocytes and leucocytes, leakage of plasma proinflammatory agents such as cytokines, and free passage of circulating SARS-CoV-2 particles to the brain parenchyma. The presence of viral particles and pro-inflammatory factors, as well as infiltrated leucocytes in cerebral tissue, triggers activation of astrocytes and microglia, which in turn causes further release of cytokines in the brain parenchyma, phagocytic hyperactivity of microglia, and disruption of astrocytes end feet, all results in more damage to the BBB and nervous tissue MAHBOUBI MEHRABANI ET AL. -11 of 21 in a rat study, an increased level of IL-1 has been indicated as a causative factor for meningitis and compromised BBB integrity. 134 Another study suggested that IL-1β induces discontinuous distribution of claudin-5, one of the TJ proteins, along the plasma membrane of brain ECs. 135 Hypoxia is a major stress factor that induces BBB disruption, leading to infiltration of peripheral immune cells and leakage of blood proteins, including cytokines, to the brain. 96 Based on the results of a study, VEGF enhances gap formation between ECs and induces fenestration in unfenestrated human and porcine endothelial monolayers in vitro. 154 Interestingly, a later study indicated that hypoxia can downregulate the expression of ZO-1, increase the expression of HIF-1α and VEGF and upregulate the phosphorylation of ZO-1, which all together can disrupt the BBB integrity and facilitate the invasion of SARS-CoV-2 into the CNS tissue. Since HIF-1α stabilisation is directly linked to barrier disruption, It is claimed that inhibition of HIF-1α improves barrier stability and decreases BBB damages, and prevents or reduces further CNS dysfunctions caused by SARS-CoV-2. 148 Nevertheless, the function of the HIF-1α inhibitor and VEGF antibody has been investigated, and according to evidence and documents, the expression of ZO-1 has been increased by inhibiting HIF-1α and VEGF. 96 It is noteworthy that HIF-1α also activates miR-let-7b, which inhibits protein expression of ACE2 and subsequently by stimulation of ADAM17 and inhibition of TMPRSS2 takes part in decreasing SARS-CoV-2 entry to the cells. 152 Remarkably, in different intensities of Covid-19 patients, there is a high probability of survival in patients with spO2 values greater than 90% with oxygen supplementation. 155 Given that hypoxaemia/hypoxia is the marker of severity, 156 and patients may be at high mortality risk, it has been speculated that in patients with spO2 values less than 90%, despite oxygen supplementation, maximum supportive care with more drug and other therapies is needed. 155 Hence, seldom drug investigations associated with hypoxic conditions are being trialed to improve the status of Covid-19 patients with hypoxia (Table 1 ). Several studies have reported coagulation abnormalities and thrombotic complications as common manifestations in patients with Covid-19. [157] [158] [159] Presented with elevated prothrombin time (PT) and D-dimer (coagulation function-related indicators), 160 163 In another study of 288 patients, thromboembolic events and acute ischaemic strokes have been reported in 7.7% and 2.5% of patients, respectively. 164 Other case series have reported the rate of stroke incidence ranging from 1% to 3% in admitted patients and up to 6% in critically ill patients. 76 Moreover, a twofold higher risk of cryptogenic stroke has been reported in Covid-19 patients, as the incidence observed in more than 65 .6% of 3556 hospitalised cases, compared to 30.4% in contemporary controls. 165 According to these clinical reports and data from previous coronavirus outbreaks, 30 hypercoagulopathy is considered a life-threatening aspect of Covid-19 pathogenesis, especially among patients with hypertension, diabetes, and other cardiovascular comorbidities. 166 Given the complexity and multifactor dependence of the mechanism, the aetiology of hypercoagulopathy in Covid-19 is not precisely explained. Downregulation of ACE2 by SARS-CoV-2 and subsequent Ang II accumulation, 167 pneumonia-induced hypoxia, 168 and release of neutrophil extracellular traps (NETs) 169 stimulates neutrophils to release excessive NETs, all resulting in a higher coagulable condition. 175 Taken together, infection-triggered complement hyperactivation induces a maladaptive inflammatory and coagulatory response, which in turn, feeds back and amplifies complement activation and clot formation. 176 Considering all the above, patients with Covid-19 are more likely to exhibit thrombotic events in multiple organs, including brain and cerebral circulation. 177, 178 The covid-19 infection has been described as a risk factor for stroke. 179 Therefore, besides ongoing anticoagulant and antiplatelet trials, administration of other possible therapeutic agents such as complement inhibitors and anti-inflammatory agents are under investigation, as they could be beneficial in targeting multiple steps of coagulation-related pathways and developing a combination therapy strategy with much more efficiency 166 (Table 1 ). Based on various case reports of various autoimmune neuropathies associated with Covid-19, it is considered that SARS-CoV-2 can also possess auto-immunogenic effects mainly via molecular mimicry or other mechanisms. [180] [181] [182] [183] Losing Immunologic tolerance to key antigenic sites on the different parts of neurons can lead to autoimmune peripheral neuropathies. 184 In other words, a potential trigger of multi-organ autoimmunity in Covid-19 could be the molecular mimicry between SARS-CoV-2 proteins and various human cell/tissue autoantigens, including the nervous system, which is involved in inflammatory polyneuropathies by analysing the peptide sharing between the virus and such protein antigens with BLAST (basic local alignment search tool). 185 Ocrelizumab is one of most widely used therapeutics for MS patients, 212 to treat relapsing and primary progressive phase of the disease. 213 In patients treated by Ocrelizumab, severe infections was found to be very low compared to patients who formerly used rituximab, which is commonly used in the population of MS patients and this group of patients is at the risk of higher rates of infections. 214 207 It is also speculated that dimethyl fumarate (DMF) may increase the risk of Covid-19 by reducing the lymphocyte count in patients. 215 In brief, clinical trials are essential for attaining more data regarding the protective or harmful effects of immunosuppressive agents, risk factors associated with severe Covid-19, and antibody formation in MS or other autoimmune patients infected by SARS-CoV-2 216 to prevent disease activation or progression and limit the need for hospitalisation in the patients suffering autoimmune diseases 213 (Table 1 ). SARS-CoV-2 could affect the nervous system in various ways. The direct invasion of the CNS by the virus could possibly occur through the infection of peripheral nerves such as OSNs, Multiple pathways of Covid-19 initiated autoimmune cascade, which may result in neurodegenerative disease severity in post-Covid-19 patients in coming decades. The cross-reactive response caused by the molecular mimicry of pathogen antigens to self-antigens, activated lymphocytes, and memory of B lymphocytes against self-antigens may lead to autoimmune response due to the interaction of antibodies with self-epitopes. Besides, initiation of central nervous system (CNS) self-tissue damage by the production of self-antigens similar to viral antigens in the structure and function of antigen presenting cells (APCs) and stimulation of T-cells by additional self-epitopes may be due to the cytokine storm and leads to an autoimmune response and further neurodegenerative complications. On the other hand, neurotoxic pro-inflammatory cytokines may have harmful effects on CNS cellular organelles such as mitochondria and lysosomes, which could be an initial point of demyelination, blood-brain barrier disintegration, and other neurodegenerative processes. SARS-CoV-2, severe acute respiratory syndrome coronavirus 2 MAHBOUBI MEHRABANI ET AL. COVID-19: a global challenge with old history, epidemiology and progress so far An update on COVID-19 pandemic: the epidemiology, pathogenesis, prevention and treatment strategies Neurological symptoms, manifestations, and complications associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) WHO declares COVID-19 a pandemic COVID-19 and headache: a primer for trainees Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China COVID-19 is a real headache! Headache Neurological manifestations in COVID-19 infection: a systematic review and meta-analysis Neurologic aspects of covid-19: a concise review SARS-CoV-2 and the nervous system: from clinical features to molecular mechanisms COVID-19 and seizures: is there a link? Viral diseases of the central nervous system Brain MRI findings in severe COVID-19: a retrospective observational study A first case of meningitis/encephalitis associated with SARS-Coronavirus-2 TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19 Cerebrospinal fluid findings in neurological diseases associated with COVID-19 and insights into mechanisms of disease development Encephalopathy in patients with COVID-19: a review Encephalitis as a clinical manifestation of COVID-19 Seizure in patients with COVID-19 Seye-dAlinaghi S. Olfactory and gustatory dysfunctions due to the coronavirus disease (COVID-19): a review of current evidence Guillain-Barré syndrome related to COVID-19 infection Demyelination as a result of an immune response in patients with COVID-19 Spectrum of neuropsychiatric manifestations in COVID-19 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study Structural and functional basis of SARS-CoV-2 entry by using human ACE2 Apostolopoulos V. Can SARS-CoV-2 virus use multiple receptors to enter host cells? The emerging role of ACE2 in physiology and disease SARS-CoV-2 virus infection: targets and antiviral pharmacological strategies SARS-CoV-2 entry in host cells-multiple targets for treatment and prevention Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past SARS-CoV-2 receptor and regulator of the reninangiotensin system: celebrating the 20th anniversary of the discovery of ACE2 Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues ACE2: evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia Mesenchymal stem cells and their derived exosomes to combat Covid-19 Association between androgen deprivation therapy and mortality among patients with prostate cancer and COVID-19 Cell entry by SARS-CoV-2 COVID-19 spike-host cell receptor GRP78 binding site prediction Can SARS-CoV-2 infect the central nervous system via the olfactory bulb or the blood-brain barrier? Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity Cell entry mechanisms of SARS-CoV-2 Understanding SARS-CoV-2 endocytosis for COVID-19 drug repurposing Potential COVID-19 therapeutic approaches targeting angiotensinconverting enzyme 2; an updated review. Reviews in Medical Virology CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells Neurological complications associated with the blood-brain barrier damage induced by the inflammatory response during SARS-CoV-2 infection Evidence of the COVID-19 virus targeting the CNS: tissue distribution, host-virus interaction, and proposed neurotropic mechanisms The expression of SARS-CoV-2 receptor ACE2 and CD147, and protease TMPRSS2 in human and mouse brain cells and mouse brain tissues Unraveling the possible routes of SARS-COV-2 invasion into the central nervous system COVID-19 transmission-up in the air Neurological manifestations of patients with COVID-19: potential routes of SARS-CoV-2 neuroinvasion from the periphery to the brain Central nervous system targets and routes for SARS-CoV-2: current views and new hypotheses Neurological involvement in COVID-19 and potential mechanisms: a review Microglial implications in SARS-CoV-2 infection and COVID-19: lessons from viral RNA neurotropism and possible relevance to Parkinson's disease Infection mechanism of SARS-COV-2 and its implication on the nervous system Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2 Severe acute respiratory syndrome coronavirus 2 infects and damages the mature and immature olfactory sensory neurons of Hamsters Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4 Self-reported olfactory and taste disorders in patients with severe acute respiratory coronavirus 2 infection: a cross-sectional study Olfactory and gustatory dysfunctions as a clinical presentation of mild-tomoderate forms of the coronavirus disease (COVID-19): a multicenter European study Diagnostic value of patient-reported and clinically tested olfactory dysfunction in a population screened for COVID-19 Olfactory dysfunction in frontline health care professionals during COVID-19 pandemic in Brazil Virus-induced neuronal dysfunction and degeneration Axonal transport enables neuron-to-neuron propagation of human coronavirus OC43 Cellular mechanisms underlying neurological/neuropsychiatric manifestations of COVID-19 Mechanisms of fast and slow axonal transport Disentangling the hypothesis of host dysosmia and SARS-CoV-2: the bait symptom that hides neglected neurophysiological routes Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Evidence for gastrointestinal infection of SARS-CoV-2 Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes The presence of SARS-CoV-2 RNA in the feces of COVID-19 patients Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from a Hong Kong cohort: systematic review and meta-analysis Digestive system involvement of novel coronavirus infection: prevention and control infection from a gastroenterology perspective Human coronaviruses and other respiratory viruses: underestimated opportunistic pathogens of the central nervous system? Viruses Neurological and neuropsychological changes associated with SARS-CoV-2 infection: new observations, new mechanisms Understanding the neurotropic characteristics of SARS-CoV-2: from neurological manifestations of COVID-19 to potential neurotropic mechanisms Effects of COVID-19 on the nervous system Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis SARS-CoV-2: is there neuroinvasion? Fluids Barriers CNS Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2 Central nervous system involvement by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Endothelial cell infection and endotheliitis in COVID-19 Expression of SARS-CoV-2-related receptors in cells of the neurovascular unit: implications for HIV-1 infection Severe acute respiratory syndrome coronavirus 2 may be an underappreciated pathogen of the central nervous system Interactions of SARS-CoV-2 with the blood-brain barrier Histological evidence for the enteric nervous system and the choroid plexus as alternative routes of neuroinvasion by SARS-CoV2. Front Neuroanat SARS-CoV-2 infects the brain choroid plexus and disrupts the blood-CSF barrier in human brain organoids SARS-CoV-2 detected in cerebrospinal fluid by PCR in a case of COVID-19 encephalitis Sars-Cov-2: underestimated damage to nervous system The blood-brain barrier The hypothalamus as a hub for SARS-CoV-2 brain infection and pathogenesis. bioRxiv; 2020 Monocyte/macrophages and their role in HIV neuropathogenesis Osteopontin facilitates West Nile virus neuroinvasion via neutrophil "Trojan horse Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review COVID-19-Associated neurological disorders: the potential route of CNS invasion and blood-brain relevance Attenuated interferon and proinflammatory response in SARS-CoV-2-infected human dendritic cells is associated with viral antagonism of STAT1 phosphorylation Propofol improved hypoxia-impaired integrity of blood-brain barrier via modulating the expression and phosphorylation of zonula occludens-1 The potential involvement of P2X7 receptor in COVID-19 pathogenesis: a new therapeutic target? COVID-19 and immunomodulation in IBD Central and peripheral nervous system involvement by COVID-19: a systematic review of the pathophysiology, clinical manifestations, neuropathology, neuroimaging, electrophysiology, and cerebrospinal fluid findings Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19 SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders Targeting MIF in cancer: therapeutic strategies, current developments, and future opportunities JAK-STAT pathway inhibition and their implications in COVID-19 therapy Neurological manifestations associated with COVID-19: a review and a call for action Cytokine storm in COVID-19: pathogenesis and overview of antiinflammatory agents used in treatment The association between HPV gene expression, inflammatory agents and cellular genes involved in EMT in lung cancer tissue Clinical and immunological features of severe and moderate coronavirus disease 2019 Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): a multicenter, single-blind, randomized controlled trial The pathogenesis and treatment of thè Cytokine Storm' in COVID-19 Targeting the NLRP3 inflammasome in severe COVID-19 The complement system in COVID-19: friend and foe? Complement as a target in COVID-19? Neurological and Neuropsychological Changes Associated with SARS-CoV-2 Infection: New Observations Potential of natural astaxanthin in alleviating the risk of cytokine storm in COVID-19 A rationale for targeting the P2X7 receptor in Coronavirus disease 19 Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology MCC950, a selective NLPR3 inflammasome inhibitor, improves neurologic function and survival after cardiac arrest and resuscitation The potential involvement of JAK-STAT signaling pathway in the COVID-19 infection assisted by ACE2 Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: the role of JAK inhibition Targeting JAK-STAT signaling to control cytokine release syndrome in COVID-19 Development, maintenance and disruption of the blood-brain barrier Establishment and dysfunction of the blood-brain barrier Functional morphology of the blood-brain barrier in health and disease The SARS-CoV-2 spike protein alters barrier function in 2D static and 3D microfluidic in-vitro models of the human blood-brain barrier Cerebrospinal fluid features in SARS-CoV-2 RT-PCR positive patients Multiple organ infection and the pathogenesis of SARS Neuroinfection may contribute to pathophysiology and clinical manifestations of COVID-19 Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology Delirium and sleep disturbances in COVID-19: a possible role for melatonin in hospitalized patients Neuropilin-1 modulates interferon-γ-stimulated signaling in brain microvascular endothelial cells Factors controlling permeability of the blood-brain barrier IL-1β promotes transendothelial migration of PBMCs by upregulation of the FN/α5β1 signalling pathway in immortalised human brain microvascular endothelial cells Peripheral inflammation and bloodbrain barrier disruption: effects and mechanisms Matrix metalloproteinases in the brain and blood-brain barrier: versatile breakers and makers Prostaglandin-cytokine crosstalk in chronic inflammation Roles of the cyclooxygenase 2 matrix metalloproteinase 1 pathway in brain metastasis of breast cancer* Neuroimmune axes of the blood-brain barriers and blood-brain interfaces: bases for physiological regulation, disease states, and pharmacological interventions Neuropathobiology of COVID-19: the role for glia. Front Cell Neurosci Interleukin-1β induces blood-brain barrier disruption by downregulating Sonic hedgehog in astrocytes The impact of microglial activation on blood-brain barrier in brain diseases Neuropathology of patients with COVID-19 in Germany: a post-mortem case series Deep spatial profiling of human COVID-19 brains reveals neuroinflammation with distinct microanatomical microglia-T-cell interactions The pathophysiology of 'happy' hypoxemia in COVID-19 Is 'happy hypoxia' in COVID-19 a disorder of autonomic interoception? A hypothesis Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation Hypoxia and innate immunity: keeping up with the HIFsters Increased expression of hypoxia-induced factor 1α mRNA and its related genes in myeloid blood cells from critically ill COVID-19 patients HIF-1α, and COVID-19: from pathogenic factors to potential therapeutic targets Cytokine-mediated dysregulation of zonula occludens-1 properties in human brain microvascular endothelium The blood-brain barrier: an overview: structure, regulation, and clinical implications Association between hypoxemia and mortality in patients with COVID-19 Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Venous thromboembolic events in patients with COVID-19: a systematic review and meta-analysis Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China COVID-19 and its implications for thrombosis and anticoagulation Coronavirus disease 2019 and stroke: clinical manifestations and pathophysiological insights Clinical characteristics of coronavirus disease 2019 in China Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in SARS-CoV-2 and stroke in a New York healthcare system Thrombocytopathy and endotheliopathy: crucial contributors to COVID-19 thromboinflammation Induced dysregulation of ACE2 by SARS-CoV-2 plays a key role in COVID-19 severity COVID-19 and peripheral artery thrombosis: a mini review Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome Multiorgan and renal tropism of SARS-CoV-2 Rapid endotheliitis and vascular damage characterize SARS-CoV-2 infection in a human lung-on-chip model COVID-19 cytokine storm: the interplay between inflammation and coagulation Coagulation and sepsis Immunity, endothelial injury and complement-induced coagulopathy in COVID-19 COVID-19: a collision of complement, coagulation and inflammatory pathways Is the COVID-19 thrombotic catastrophe complement-connected? Megakaryocytes and platelet-fibrin thrombi characterize multi-organ thrombosis at autopsy in COVID-19: a case series COVID-19 is, in the end, an endothelial disease COVID-19 and stroke-a global World Stroke Organization perspective SARS-CoV-2-associated Guillain-Barre syndrome in 62 patients Autoimmune and inflammatory diseases following COVID-19 Guillain-Barré syndrome: the first documented COVID-19-triggered autoimmune neurologic disease: more to come with myositis in the offing Guillain-Barré syndrome associated with SARS-CoV-2 Pathogenesis of immune-mediated neuropathies SARS-CoV-2 and Guillain-Barré syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism Guillain-Barré syndrome, SARS-CoV-2 and molecular mimicry Molecular mimicry in the post-COVID-19 signs and symptoms of neurovegetative disorders? COVID-19 as a trigger of brain autoimmunity Guillain Barré Syndrome and its variants as a manifestation of COVID-19: a systematic review of case reports and case series Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence? Neurological associations of COVID-19 COVID-19 vaccine and Guillain-Barré syndrome: let's not leap to associations Guillain-Barré syndrome spectrum associated with COVID-19: an upto-date systematic review of 73 cases Incidence, clinical, risk factors and outcomes of Guillain-Barré in Covid-19 Guillain-Barré syndrome and COVID-19: an observational multicentre study from two Italian hotspot regions GM1 ganglioside antibody and COVID-19 related Guillain Barre Syndrome -a case report, systemic review and implication for vaccine development Covid-19 and autoimmunity Emerging infection, vaccination, and Guillain-Barré syndrome: a review IVIG treatment and prognosis in Guillain-Barré syndrome Intravenous immunoglobulin immunotherapy for coronavirus disease-19 (COVID-19) Treatment of a case of COVID-19 by intravenous immunoglobulin IVIg-induced plasmablasts in patients with Guillain-Barré syndrome IVIG therapy in neurological disorders of childhood COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable? COVID-19 infection in a patient with multiple sclerosis treated with fingolimod Impact of COVID-19 on U.S. and Canadian neurologists' therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices Impact of diseasemodifying drugs on the severity of COVID-19 infection in multiple sclerosis patients Multiple sclerosis and the risk of infection: considerations in the threat of the novel coronavirus, COVID-19/SARS-CoV-2 Infections in patients diagnosed with multiple sclerosis: a multi-database study COVID-19 in ocrelizumabtreated people with multiple sclerosis COVID-19 in multiple sclerosis patients and risk factors for severe infection COVID-19 in persons with multiple sclerosis treated with ocrelizumab -a pharmacovigilance case series The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies COVID-19 in dimethyl fumarate-treated patients with multiple sclerosis COVID-19 in multiple sclerosis: the Dutch experience Neurological complications associated with Covid-19; molecular mechanisms and therapeutic approaches The authors would like to express very great appreciation to Mr.Mohammad H Azhdari and Mr. Nima Goodarzi for generation of graphical abstracts and schematic figures of this study. The authors declare that there is no conflict of interest.